No Data
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND
Athena Gold Upsizes Private Placement From C$1M to up to C$1.25M
Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline
Althira Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Express News | Althira Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results
JMP Securities Maintains Athira(ATHA.US) With Hold Rating
凑仔公阿当 : I hope so